MediLens Intelligence
Features

Medical Research Trends

This week's highest-impact publications across 29 specialties, curated by AI

Last updated: 11 de mai. de 2026

Gastroenterology5 articles

Impact 2

Gut microbiota-regulated glutathione metabolic rhythms restore obesity-induced colonic inflammatory oscillations.

Published: 2026-12-31

Gut microbes

MediLens Indexed: 2026-05-11

The study investigates the impact of obesity on circadian inflammatory rhythms, a key aspect of metabolic syndrome. It demonstrates that a high-fat diet disrupts microbiota-regulated glutathione metabolism, leading to altered colonic inflammatory rhythms. The use of fructo-oligosaccharide (FOS) a...

Read on PubMed
Impact 2

Endoscopic grading of gastric intestinal metaplasia and microvascular pattern for assessing gastric cancer risk: a prospective study.

Published: 2026-12-01

Annals of medicine

MediLens Indexed: 2026-05-12

This study validates the diagnostic accuracy of the endoscopic grading of gastric intestinal metaplasia (EGGIM) for identifying high-risk gastric intestinal metaplasia (GIM) patients. A total of 144 patients were evaluated, revealing an area under the curve (AUC) of 0.885 for EGGIM in diagnosing ...

Read on PubMed
Impact 3

Significant Intra-pancreatic Fat Deposition as an Independent Prognostic Factor in High-grade Pancreatic Neuroendocrine Neoplasms.

Published: 2026-05-11

Annals of surgical oncology

MediLens Indexed: 2026-05-12

This study evaluates the prognostic value of significant intra-pancreatic fat deposition (IPFD) in patients with high-grade pancreatic neuroendocrine neoplasms (panNENs). Among 87 patients, 27.6% exhibited significant IPFD, which was linked to worse overall and disease-specific survival outcomes....

Read on PubMed
Impact 2

Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis.

Published: 2026-05-11

Inflammatory bowel diseases

MediLens Indexed: 2026-05-12

This systematic review evaluated the efficacy of advanced therapies for treating extraintestinal manifestations (EIMs) in inflammatory bowel diseases (IBDs). It included 49 studies, revealing that TNF antagonists and JAK inhibitors were effective for musculoskeletal EIMs, with response rates of 6...

Read on PubMed
Impact 2

Real-world outcomes of pembrolizumab in advanced anal cancer: a nationwide Danish anal Cancer Group report.

Published: 2026-05-11

Acta oncologica (Stockholm, Sweden)

MediLens Indexed: 2026-05-12

This study investigates the effectiveness of pembrolizumab in treating advanced squamous cell carcinoma of the anal canal (SCCA) in a real-world cohort of 37 Danish patients. The objective response rate was 13.5%, with a clinical benefit rate of 48.6%. Median progression-free survival was 4.0 mon...

Read on PubMed

Get Personalized Daily Summaries

Join physicians worldwide who start their morning with AI-curated literature reviews, delivered to your inbox at 7 AM.

Start 14-Day Free Trial